Literature DB >> 19681899

The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?

Christopher Chapple1, Dirk De Ridder.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19681899     DOI: 10.1111/j.1464-410X.2009.08777.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  5 in total

Review 1.  Voiding dysfunction in the female patient: is the "syndrome" paradigm valid?

Authors:  Hari Siva G R Tunuguntla; Renuka Tunuguntla; Joseph Barone; Prashanth Kanagarajah; Angelo E Gousse
Journal:  Curr Urol Rep       Date:  2011-10       Impact factor: 3.092

Review 2.  The use of botulinum toxin a in idiopathic overactive bladder syndrome.

Authors:  Christopher S Gomez; Prashanth Kanagarajah; Angelo Gousse
Journal:  Curr Urol Rep       Date:  2010-09       Impact factor: 3.092

3.  Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity.

Authors:  Prashanth Kanagarajah; Rajinikanth Ayyathurai; Daniel J Caruso; Christopher Gomez; Angelo E Gousse
Journal:  Int Urol Nephrol       Date:  2011-06-04       Impact factor: 2.370

4.  What is the predictive value of urodynamics to reproduce clinical findings of urinary frequency, urge urinary incontinence, and/or stress urinary incontinence?

Authors:  Daniel J Caruso; Prashanth Kanagarajah; Brian L Cohen; Rajinikanth Ayyathurai; Christopher Gomez; Angelo E Gousse
Journal:  Int Urogynecol J       Date:  2010-06-18       Impact factor: 2.894

5.  The surgical management of the refractory overactive bladder.

Authors:  Nikhil Vasdev; Benjamin D Biles; Raveen Sandher; Tahseen S Hasan
Journal:  Indian J Urol       Date:  2010-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.